Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Classement en actions #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Prix de l'action
$9.60
Dernière synchronisation: 2025-05-21
Capitalisation boursière
$1.08B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange OptiNose, Inc. (OPTN)

Catégorie

Bénéfices pour OptiNose, Inc. (OPTN)
Bénéfices en Mar 2025 TTM : $-29.89M
Selon les derniers rapports financiers de OptiNose, Inc., les bénéfices actuels de l'entreprise sont de $-29.89M. En 2023, l'entreprise a réalisé un bénéfice de $-35.48M, une augmentation par rapport à celui de 2022 qui était de $-74.83M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour OptiNose, Inc. de 2015 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-29.89M 38.76%
2024 $-21.54M -39.29%
2023 $-35.48M -52.58%
2022 $-74.83M -9.07%
2021 $-82.30M -17.53%
2020 $-99.79M -9.33%
2019 $-110.05M 3.18%
2018 $-106.66M 118.11%
2017 $-48.90M -316.26%
2016 $22.61M -179.87%
2015 $-28.31M 0.00%
Bénéfices des entreprises similaires ou concurrentes